ASX 200 plunges as US tariffs fall-out continues

The ASX 200 benchmark index fell by almost 200 points on Friday.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) plummeted by 191.9 points or 2.44% on Friday to finish the week at 7,667.8 points.

Uncertainty about how the newly announced reciprocal US tariffs will impact ASX 200 shares fuelled today's dive.

Based on closing values, today's market rout has pushed the ASX 200 into an official market correction.

A market correction is defined as a major index falling 10% from its most recent peak.

The ASX 200 narrowly avoided a correction last month after it fell 9.43% from its record high on 14 February to a trough on 13 March.

The fall saw several blue-chip shares trading at multi-year lows, including Fortescue Ltd (ASX: FMG) and CSL Ltd (ASX: CSL).

The ASX 200 began a rebound on 14 March, but this week's US tariffs news has brought that undone.

The ASX 200 closed down 10.38% from its 14 February high today.

Today, we heard from more companies about the potential impact of the tariffs on their operations.

Let's take a look.

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.

Image source: Getty Images

ASX 200 dives as more companies reveal US tariff impact

Amotiv Ltd (ASX: AOV)

The Amotiv share price closed 16.72% lower at $7.32 after the auto parts retailer issued a trading update and commented on the US tariffs.

Amotiv said:

In response to these recent tariff announcements, the Group is assessing a range of tactical and strategic actions to manage the risks and realise the opportunities of these changes.

These include re-sourcing of finished goods, re-pricing and use of alternative manufacturing and supply locations.

Mesoblast Ltd (ASX: MSB)

Mesoblast shares closed 5.87% lower at $1.77.

The ASX 200 biotech company sought to reassure investors today.

In a statement, it said:

Mesoblast allogeneic cell therapy products are designated 'U.S. country of origin' and not subject to U.S. tariffs.

Ansell Ltd (ASX: ANN)

Ansell shares closed 3% higher at $30.22 today.

The company issued a statement saying it would "fully offset the tariff increases through pricing".

Ansell said approximately 43% of its revenue comes from the US.

The majority of products sold in the US are imported from Malaysia, Sri Lanka, Thailand, Vietnam, and China.

The company said:

Ansell plans to fully offset the tariff increases through pricing, and we have had conversations with customers to this effect including in the past 24 hours.

It is worth noting that the vast majority of manufacturing in our industry is conducted in Asian countries now subject to US tariffs, and US industry manufacturing capacity for comparable hand and body protection products is negligible.

Longer term, Ansell retains the flexibility to respond to changes in the relative attractiveness of traditional PPE manufacturing locations through 14 owned manufacturing plants in 9 countries and our extensive partner network.

Breville Group Ltd (ASX: BRG)

The ASX 200 consumer discretionary stock closed 12.01% lower at $26.44 on Friday, compounding a 5% decline on Thursday.

Breville issued a statement on the US tariffs yesterday:

Subject to the current uncertainty and fluidity in the economic environment, US tariff implementation and iteration, coupled with any country-specific responses, it is likely that the Group's input costs will increase for FY26.

The Group will continue to make tactical adjustments, where appropriate, to lessen the potential short-term impacts from any new tariffs.

CSL Ltd (ASX: CSL)

The CSL share price closed 1.7% lower at $253.30.

In a statement, the ASX 200 healthcare giant said:

At this stage pharmaceutical products are not subject to the reciprocal tariffs.

CSL is continuing to assess the broader impact of the tariffs and will monitor further announcements by the U.S. Government.

You can check out a complete reciprocal US tariffs list by country here.

Motley Fool contributor Bronwyn Allen has positions in CSL and Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Ansell and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Two men celebrate while another holds his head in his hands, after watching the race.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a strange day on the ASX.

Read more »

Rocket going up above mountains, symbolising a record high.
Broker Notes

2 ASX mining shares tipped by experts to rocket 55% to 85%

One is a copper miner, the other is an iron ore producer.

Read more »

Happy miner with his hand in the air.
Resources Shares

BHP shares just hit a new all-time high. Here's why

The Big Australian has a big new share price to match it.

Read more »

A happy person clenching fists in celebration sitting at computer.
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »

graphic image of a crown dropping on its side and shattering
Share Market News

BHP shares regain their market crown as CBA slides 10%

The 'Big Australian' is once again at the top of the ASX 200.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Broker Notes

3 ASX 200 shares predicted to double over 12 months

These stocks are on a different trajectory to the ASX 200, which has slipped into the red for 2026.

Read more »

Six smiling health workers pose for a selfie.
Broker Notes

3 reasons this beaten down ASX All Ords healthcare share could come roaring back

A leading analyst believes this beaten down ASX healthcare stock is well-positioned for a comeback.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Healthcare Shares

Down 59%: Will CSL shares ever regain momentum?

Here's what to expect over the next 12 months.

Read more »